Suzhou Youseen

Suzhou Youseen is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to the discovery and development of novel small molecule drugs for oncology and immunology. The company utilizes a proprietary structure-based drug design platform to target key signaling pathways involved in cancer progression and immune evasion. Its lead candidate, USN-007, is a highly selective inhibitor of Hematopoietic progenitor kinase 1 (HPK1) currently in Phase 1 clinical trials for patients with advanced solid tumors. Suzhou Youseen's pipeline also includes several early-stage programs focused on differentiated mechanisms of action to provide new treatment options for unmet medical needs. The firm is backed by prominent venture capital investors and operates within the BioBAY life sciences hub.